Results for: Orphan Drugs

The orphan drugs market is experiencing significant growth, driven by advancements in biotechnology, increased understanding of rare diseases, and favorable regulatory environments. This market segment is projected to reach US$ 424.0 billion by 2034, driven by the increasing demand for personalized medicine solutions and the development of innovative treatments for rare diseases.

Despite promising research, many biopharma companies have abandoned genetic therapies for ultra-rare diseases due to limited profit potential. However, Great Ormond Street Hospital in London is taking an unusual step to get a treatment approved on its own.